Is Bristol-Myers Squibb Company (BMY) The Best Beaten Down Dividend Stocks to Invest in Now?
We recently compiled a list of the 10 Best Beaten Down Dividend Stocks to Invest in Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other beaten down dividend stocks.
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
Bristol Myers Squibb Co. closed $10.05 below its 52-week high ($59.46), which the company reached on September 22nd.
With 77% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing
Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.
Bristol Myers Squibb Dividend Yield Pushes Past 5%
In trading on Monday, shares of Bristol Myers Squibb were yielding above the 5% mark based on its quarterly dividend (annualized to $2.4)
What Analysts Are Saying About Bristol-Myers Squibb Stock
In the assessment of 12-month price targets, analysts unveil insights for Bristol-Myers Squibb, presenting an average target of $46.0, a high estimate of $53.00, and a low estimate of $41.00. Witnessing a positive shift, the current average has risen by 0.26% from the previous average price target of $45.88.
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High
Bristol Myers Squibb (NYSE: BMY) has struggled to manage the loss of exclusivity now that some of its top-selling drugs are facing competition from generics. Disappointing results from the pharmaceutical giant have pressured the stock in recent years; it's currently down about 34% from its record high in 2022.
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day
Shares of Bristol Myers Squibb Co. BMY slipped 1.40% to $48.59 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.07% to 5,
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Bristol-Myers Squibb: Hold Rating Justified by Market-Reflected Approval of KarXT Despite Promising Clinical Data
BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...
What's Going On With ACADIA Pharmaceuticals Stock?
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) shares are trading lower by 4.11% to $15.62 during Tuesday’s session after the ...
FiercePharma4d
Bristol Myers Squibb axes 79 more in New Jersey as $1.5B cost-reduction program rolls on
The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program.  | Bristol Myers ...
Bristol-Myers Squibb (BMY): Hold Rating Justified by Mixed Growth Prospects and Pipeline Catalysts
Wells Fargo analyst Mohit Bansal maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) on September 6 and set a price ...